A detailed history of Goelzer Investment Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Goelzer Investment Management, Inc. holds 130,836 shares of BMY stock, worth $6.96 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
130,836
Previous 132,949 1.59%
Holding current value
$6.96 Million
Previous $5.52 Million 22.62%
% of portfolio
0.37%
Previous 0.31%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$39.66 - $51.75 $83,801 - $109,347
-2,113 Reduced 1.59%
130,836 $6.77 Million
Q2 2024

Aug 09, 2024

SELL
$40.25 - $52.99 $176,415 - $232,255
-4,383 Reduced 3.19%
132,949 $5.52 Million
Q1 2024

May 01, 2024

SELL
$47.98 - $54.4 $66,836 - $75,779
-1,393 Reduced 1.0%
137,332 $7.45 Million
Q4 2023

Feb 07, 2024

SELL
$48.48 - $57.85 $29,912 - $35,693
-617 Reduced 0.44%
138,725 $7.12 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $280,129 - $313,228
-4,839 Reduced 3.36%
139,342 $8.09 Million
Q2 2023

Jul 26, 2023

SELL
$63.71 - $70.74 $80,911 - $89,839
-1,270 Reduced 0.87%
144,181 $9.22 Million
Q1 2023

Apr 27, 2023

BUY
$65.71 - $74.53 $1.11 Million - $1.26 Million
16,896 Added 13.14%
145,451 $10.1 Million
Q4 2022

Jan 20, 2023

SELL
$68.48 - $81.09 $152,778 - $180,911
-2,231 Reduced 1.71%
128,555 $0
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $495 - $292,606
3,808 Added 3.0%
130,786 $9.3 Million
Q2 2022

Aug 01, 2022

BUY
$72.62 - $79.98 $454,310 - $500,354
6,256 Added 5.18%
126,978 $9.78 Million
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $80,600 - $96,646
-1,311 Reduced 1.07%
120,722 $8.82 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $1.57 Million - $1.83 Million
-29,310 Reduced 19.37%
122,033 $7.61 Million
Q3 2021

Oct 29, 2021

SELL
$59.17 - $69.31 $320,523 - $375,452
-5,417 Reduced 3.46%
151,343 $8.96 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $4.13 Million - $4.5 Million
-66,683 Reduced 29.84%
156,760 $10.5 Million
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $177,663 - $199,819
2,994 Added 1.36%
223,443 $14.1 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $198,163 - $224,555
-3,432 Reduced 1.53%
220,449 $13.7 Million
Q3 2020

Oct 27, 2020

SELL
$57.43 - $63.64 $213,409 - $236,486
-3,716 Reduced 1.63%
223,881 $13.5 Million
Q2 2020

Aug 12, 2020

SELL
$54.82 - $64.09 $76,528 - $89,469
-1,396 Reduced 0.61%
227,597 $13.4 Million
Q1 2020

May 07, 2020

BUY
$46.4 - $67.43 $63,196 - $91,839
1,362 Added 0.6%
228,993 $12.8 Million
Q4 2019

Feb 07, 2020

SELL
$49.21 - $64.19 $65,547 - $85,501
-1,332 Reduced 0.58%
227,631 $14.6 Million
Q3 2019

Nov 06, 2019

BUY
$42.77 - $50.71 $324,880 - $385,193
7,596 Added 3.43%
228,963 $11.6 Million
Q2 2019

Jul 29, 2019

BUY
$44.62 - $49.34 $2.85 Million - $3.15 Million
63,896 Added 40.58%
221,367 $10 Million
Q1 2019

May 03, 2019

BUY
$45.12 - $53.8 $3.84 Million - $4.57 Million
85,002 Added 117.29%
157,471 $7.51 Million
Q4 2018

Jan 28, 2019

BUY
$48.76 - $63.23 $2.04 Million - $2.65 Million
41,916 Added 137.19%
72,469 $3.77 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $32,286 - $36,416
-585 Reduced 1.88%
30,553 $1.9 Million
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $92,874 - $115,757
-1,838 Reduced 5.57%
31,138 $1.72 Million
Q1 2018

May 07, 2018

SELL
$59.92 - $68.98 $2.66 Million - $3.06 Million
-44,371 Reduced 57.37%
32,976 $2.09 Million
Q4 2017

Feb 06, 2018

BUY
$59.94 - $65.35 $133,666 - $145,730
2,230 Added 2.97%
77,347 $4.74 Million
Q3 2017

Oct 31, 2017

BUY
$55.23 - $63.74 $4.15 Million - $4.79 Million
75,117
75,117 $4.79 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Goelzer Investment Management, Inc. Portfolio

Follow Goelzer Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goelzer Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Goelzer Investment Management, Inc. with notifications on news.